Sitagliptin

Generic Name: Sitagliptin

Brand Names: Janumet, Januvia, Ristaben, Steglujan, Tesavel, Velmetia, Xelevia, Sitagliptin SUN, Sitagliptin Accord

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₅F_₆N_₅O

CAS Number: 486460-32-6

Unique Ingredient Identifier: QFP0P1DV7Z

Background: Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar. Sitagliptin was granted FDA approval on Oct...

Indication: Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.

It is also used in combination with metformin or ertugliflozin.

Associated Conditions: Type 2 Diabetes Mellitus

Associated Therapies: -

Clinical Trials

Effects of a Dipeptidyl Peptidase-4 Inhibitor Sitagliptininsulin on the Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes

Phase 4

Conditions: Atherosclerosis Type 2 Diabetes Mellitus Dipeptidyl Peptidase-4 Inhibitor GLP-1

Interventions: Drug: Sitagliptin
Drug: Acarbose

First Posted Date: 2018-07-27

Last Posted Date: 2018-07-27

Lead Sponsor: Chinese PLA General Hospital

Target Recruit Count: 300

Registration Number: NCT03602638

Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease

Phase 4

Completed

Conditions: Diabetes Mellitus
Coronary Disease

Interventions: Drug: Empagliflozin
Drug: Sitagliptin

First Posted Date: 2017-07-05

Last Posted Date: 2019-08-07

Lead Sponsor: CHEOL WHAN LEE, M.D., Ph.D

Target Recruit Count: 100

Registration Number: NCT03208465

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance and Type 2 Diabetes in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome

Phase 4

Completed

Conditions: PCOS

Interventions: Drug: Sitagliptin
Behavioral: Lifestyle intervention

First Posted Date: 2017-04-20

Last Posted Date: 2017-04-20

Lead Sponsor: University Medical Centre Ljubljana

Target Recruit Count: 30

Registration Number: NCT03122041

A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: LY3325656
Drug: Placebo
Drug: Liraglutide
Drug: Sitagliptin

First Posted Date: 2017-04-14

Last Posted Date: 2018-08-23

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 80

Registration Number: NCT03115099

Locations: 🇸🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore, Singapore
🇸🇬
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician., Singapore, Singapore

Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Sitagliptin
Drug: Bexagliflozin
Drug: Placebo for bexagliflozin
Drug: Placebo for sitagliptin

First Posted Date: 2017-04-14

Last Posted Date: 2021-06-22

Lead Sponsor: Theracos

Target Recruit Count: 386

Registration Number: NCT03115112

Locations: 🇵🇱
Clinical Research Site 7138, Lublin, Poland
🇵🇱
Clinical Research Site 7137, Gdańsk, Poland
🇵🇱
Clinical Research Site 7141, Kraków, Poland

and more 53 locations